卡铂联合紫杉醇对比顺铂联合紫杉醇在理想减灭的III期卵巢癌患者中的III期试验:一项妇科肿瘤组研究
这项非劣效性III期随机试验纳入792例术后残留灶不超过1.0 cm的晚期卵巢癌患者,比较顺铂75 mg/m2加24小时紫杉醇135 mg/m2(第I组)与卡铂曲线下面积7.5加3小时紫杉醇175 mg/m2(第II组)。卡铂联合紫杉醇毒性更少、给药更方便且不劣于顺铂联合紫杉醇。
要点
- 第I组胃肠道、肾脏、代谢毒性及4级白细胞减少显著更常见,第II组2级及以上血小板减少更常见。
- 第I组中位无进展生存期19.4个月、总生存期48.7个月;第II组分别为20.7个月和57.4个月。
- 卡铂联合紫杉醇组进展相对风险0.88(95%CI 0.75-1.03),死亡相对风险0.84(95%CI 0.70-1.02)。
核心结论
- 在晚期卵巢癌患者中,卡铂联合紫杉醇方案毒性更少、给药更方便,且不劣于顺铂联合紫杉醇。
研究设计与样本
- 随机非劣效性III期试验,纳入792例术后无大于1.0 cm残留肿块的晚期卵巢癌患者。
- 第I组接受顺铂75 mg/m2加24小时输注紫杉醇135 mg/m2;第II组接受卡铂曲线下面积7.5静脉给药加3小时输注紫杉醇175 mg/m2。
主要发现
- 第I组胃肠道、肾脏、代谢毒性及4级白细胞减少显著更常见;第II组2级及以上血小板减少更常见;两组神经毒性相似。
- 第I组中位无进展生存期19.4个月、总生存期48.7个月;第II组分别为20.7个月和57.4个月。
- 卡铂联合紫杉醇组进展相对风险0.88(95%CI 0.75-1.03),死亡相对风险0.84(95%CI 0.70-1.02)。
关键数值与推荐
- 第I组顺铂75 mg/m2加24小时输注紫杉醇135 mg/m2;第II组卡铂曲线下面积7.5加3小时输注紫杉醇175 mg/m2。
- 卡铂联合紫杉醇组进展相对风险0.88(95%CI 0.75-1.03),死亡相对风险0.84(95%CI 0.70-1.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in nonrandomized trials, carboplatin and paclitaxel was a less toxic and highly active combination regimen, there remained concern regarding its efficacy in patients with small-volume, resected, stage III disease. Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population.Patients and Methods: Patients with advanced ovarian cancer and no residual mass greater than 1.0 cm after surgery were randomly assigned to receive cisplatin 75 mg/m2 plus a 24-hour infusion of paclitaxel 135 mg/m2 (arm I), or carboplatin area under the curve 7.5 intravenously plus paclitaxel 175 mg/m2 over 3 hours (arm II).Results: Seven hundred ninety-two eligible patients were enrolled onto the study. Prognostic factors were similar in the two treatment groups. Gastrointestinal, renal, and metabolic toxicity, as well as grade 4 leukopenia, were significantly more frequent in arm I. Grade 2 or greater thrombocytopenia was more common in arm II. Neurologic toxicity was similar in both regimens. Median progression-free survival and overall survival were 19.4 and 48.7 months, respectively, for arm I compared with 20.7 and 57.4 months, respectively, for arm II. The relative risk (RR) of progression for the carboplatin plus paclitaxel group was 0.88 (95% confidence interval [CI], 0.75 to 1.03) and the RR of death was 0.84 (95% CI, 0.70 to 1.02).Conclusion: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.
引用
- Ozols RF, Bundy BN, Greer BE, et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2023. PMID: 37643542. doi:10.1200/JCO.22.02766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。